Denali Therapeutics (DNLI) EBITDA (2017 - 2026)
Denali Therapeutics (DNLI) reported EBITDA of -$129.8 million for Q1 2026, up 2.36% year-over-year from -$126.8 million in Q1 2025, and down 0.65% quarter-over-quarter from -$129.0 million in Q4 2025.
Denali Therapeutics (DNLI) EBITDA (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of EBITDA data on file, last reported at -$129.8 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$129.8 million, up 2.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$510.7 million (down 13.34% YoY), and the FY2025 annual result was -$513.9 million, down 21.95% from the prior year.
- EBITDA retreated to -$129.8 million in Q1 2026 per DNLI's latest filing, from -$129.0 million in the prior quarter.
- Over five years, EBITDA peaked at $184.5 million in Q2 2023 and troughed at -$133.0 million in Q1 2025.
- A 5-year average of -$90.2 million and a median of -$103.7 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA soared 398.4% in 2023, then sank 154.42% in 2024.
- A 5-year view of EBITDA shows it stood at -$93.7 million in 2022, then slipped by 26.11% to -$118.2 million in 2023, then slipped by 0.07% to -$118.3 million in 2024, then declined by 9.05% to -$129.0 million in 2025, then dropped by 0.65% to -$129.8 million in 2026.
- Business Quant data shows DNLI's EBITDA at -$129.8 million in Q1 2026, -$129.0 million in Q4 2025, and -$126.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -129.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.81 Mn |
| Dec 31, 2025 | -128.97 Mn |
| Sep 30, 2025 | -126.74 Mn |
| Jun 30, 2025 | -125.22 Mn |
| Mar 31, 2025 | -132.95 Mn |
| Dec 31, 2024 | -118.26 Mn |
| Sep 30, 2024 | -99.00 Mn |
| Jun 30, 2024 | -100.39 Mn |
| Mar 31, 2024 | -103.74 Mn |
| Dec 31, 2023 | -118.18 Mn |
| Sep 30, 2023 | -98.56 Mn |
| Jun 30, 2023 | 184.46 Mn |
| Mar 31, 2023 | -105.41 Mn |
| Dec 31, 2022 | -93.71 Mn |
| Sep 30, 2022 | -102.88 Mn |
| Jun 30, 2022 | -61.82 Mn |
| Mar 31, 2022 | -71.97 Mn |
| Dec 31, 2021 | -77.24 Mn |
| Sep 30, 2021 | -84.74 Mn |
| Jun 30, 2021 | -60.83 Mn |